GTC Biotherapeutics (fka GTCB)

[go seek]

How much do ya figure the P2 ATryn DIC trial will cost LEO?

Leo will fund 100% of the phase-2 development in the DIC indication. When this program enters phase-3, GTC will have the option—but not the obligation—to fund half of the clinical-trial expenses. If GTC exercises this option, it will have access to all of Leo’s phase-3 data for use in the U.S. and Japan—territories not covered by the Leo partnership; if GTC declines to exercise the option, it will have access to only the phase-2 data. (GTC’s decision to exercise or not exercise this option will presumably depend on how important the European data will be to the FDA and the Japanese regulators.)



The creation of a thousand forests is in one acorn.